TRAX First Tracks Biotherapeutics, I
$45.38▲ +4.37%
Healthcare
Other
After hours
$45.70▲ +0.71%
Oct 27, 5:36 PM ET
Volume 617.7K
Avg Volume (10D) 1.02M
Key Metrics & Fundamentals
Market Cap
$1.91B
P/E Ratio
–
Div Yield
0.00%
52W Range
14.72 - 49.91
% vs 50 MA
16.89%
% vs 200 MA
–%
RSI-14
67.5
MACD Histogram
+1.4600
Beta (1Y vs SPY)
2.61
Free Cash Flow
-$31.94M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$34.73M
COGS
–
Operating Exp
$34.94M
Operating Income
-$34.94M
EBIT
-$34.94M
Pretax Income
-$33.37M
Net Income
-$33.37M
EPS (Diluted)
-0.95
Price & Volume History
Loading chart…
Recent News
First Tracks Biotherapeutics Announces $200 Million Private Placement
MT Newswires · Oct 15, 2026 8:52 AM ET
First Tracks Biotherapeutics Announces $200 Million Private Placement
GlobeNewswire · Oct 15, 2026 8:00 AM ET
Top biotechnology stock pick from Guggenheim
Investing.com · Oct 14, 2026 2:54 PM ET
7 Reasons First Tracks Biotherapeutics (TRAX) Looks Pricey Following ANB033 Trial Data
Simply Wall St. · Oct 13, 2026 8:18 AM ET
First Tracks Biotherapeutics (TRAX) Stock Looks Rich Following Phase 1b Celiac Data
Simply Wall St. · Oct 13, 2026 7:16 AM ET
First Tracks Biotherapeutics (TRAX) Reports Positive Phase 1b Cohort 1 Results
Simply Wall St. · Oct 13, 2026 6:12 AM ET
First Tracks climbs on ‘impressive’ celiac study data
BioPharma Dive · Oct 12, 2026 5:26 PM ET
Why This IPO Stock, An AnaptysBio Spinoff, Just Surged
Investor's Business Daily · Oct 12, 2026 4:10 PM ET
Sector Update: Healthcare Stocks Advance in Afternoon Trading
MT Newswires · Oct 12, 2026 1:41 PM ET
First Tracks’ ANB033 Clears Key Phase Ib Celiac Disease Study Goals
MarketBeat · Oct 12, 2026 1:02 PM ET
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See TRAX's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.